Although majority of Takayasu arteritis (TA) pregnancies are uneventful and have favourable foetal and maternal outcomes, pregnant TA patients with active disease are at increased risk of developing maternal complications, particularly cardiovascular events, according to a study presented at the European League Against Rheumatism (EULAR) Congress 2018.
Denosumab yields increases in bone mineral density (BMD) in patients with glucocorticoid-induced osteoporosis (GIOP), and this benefit is not influenced by prior antiosteoporotic treatment, as shown in a study.
While self-reported adherence to treatment appears to be high for both systemic lupus erythematosus and vasculitis, patient forgetfulness remains a strong barrier, according to a research presented at the 2018 Annual European Congress of Rheumatology (EULAR 2018).
Among children with juvenile idiopathic arthritis, the risk of developing uveitis is not greater in those treated with etanercept than in those receiving methotrexate, according to a study presented at the European League Against Rheumatism (EULAR) 2018 Congress.
Fibromyalgia occurs commonly in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis, with disease activity seemingly greater in the presence of fibromyalgia, a study reports.
The selective cannabinoid receptor type 2 agonist lenabasum exhibited an acceptable safety profile while improving outcomes in patients with diffuse cutaneous systemic sclerosis, according to results of a phase II study.
Hydroxychloroquine (HCQ) inhibits the differentiation of Th17 cells and production of interleukin 17 (IL-17) both in vitro and in patients with systemic lupus erythematosus (SLE), a recent study has shown.
Analysis of pooled data from three phase III trials (SPIRIT-P1, -P2 and -P3) reveals that ixekizumab (IXE), a high affinity monoclonal antibody that selectively targets interleukin-17A, is a safe treatment for patients with active psoriatic arthritis (PsA), according to a study presented at the Annual European Congress of Rheumatology by the European League Against Rheumatism (EULAR 2018).
Diacerein appears to be more effective than glucosamine plus chondroitin for patients with mild-to-moderate knee osteoarthritis , according to a study presented at the 2018 Annual European Congress of Rheumatology (EULAR 2018).
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.
Age, weight, oral corticosteroid use and strenuous exercise at age 18 years appear to be useful in predicting the 5-year risk of height loss of at least 1 inch in postmenopausal women, according to a study.